TET2 and melanoma: In contrast, six of 38 (15.8 %) of our human melanoma samples had a documented mutation in TET2. Moreover, when including IDH1-mutant samples, 21 % (8 of 38) of patient samples had at least one mutation affecting the critical DNA demethylation pathway in which these two enzymes participate.